Figure 1.

Patient flow. The subgroups of patients starting IFN during pregnancy and those who paused or stopped during pregnancy were not mutually exclusive and overlapped in 12 cases in the population with confirmed exposure dates. *The live birth population consisted of seven pregnancies with continuous exposure, 5 pregnancies, in which IFN was started during pregnancy, 2 pregnancies, in which IFN was paused during pregnancy and restarted within 1 week postpartum, 96 pregnancies, in which IFN was paused during pregnancy and restarted >1 week postpartum, 20 pregnancies, in which IFN was stopped during pregnancy and not restarted postpartum, and 62 pregnancies, in which IFN therapy was either stopped before pregnancy or data was missing.

IFN, IM interferon beta-1a or peginterferon beta-1a; IM, intramuscular.